Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways

Cabazitaxel (CBZ) is approved for the treatment of docetaxel-resistant castration-resistant prostate cancer (CRPC). However, its efficacy against CRPC is limited, and there are no effective treatments for CBZ-resistant CRPC. This study explored the optimal treatment for CRPC in the post-cabazitaxel...

Descripción completa

Detalles Bibliográficos
Autores principales: Hongo, Hiroshi, Kosaka, Takeo, Suzuki, Yoko, Mikami, Shuji, Fukada, Junichi, Oya, Mototsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593019/
https://www.ncbi.nlm.nih.gov/pubmed/34782700
http://dx.doi.org/10.1038/s41598-021-01697-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593019/
https://www.ncbi.nlm.nih.gov/pubmed/34782700
http://dx.doi.org/10.1038/s41598-021-01697-2

Ejemplares similares